Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) issued the following statement in response to a May 18, 2009, letter which Eastbourne Capital ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE